DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications

Pharmacology and Therapeutics

Volumn 151, Issue , 2015, Pages 87-98

  Abbassi, Ramzi ^a   Johns, Terrance G ^b,c   Kassiou, Michael ^d   Munoz, Lenka ^a  

^a University of Sydney   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alzheimer's disease; Cancer; Down syndrome; Dual specificity kinases; DYRK1A; Kinase inhibitors

Indexed keywords

AZAINDOLE DERIVATIVE; BENZOTHIAZOLE DERIVATIVE; CYTOKINE; DUAL SPECIFICITY TYROSINE PHOSPHORYLATION REGULATED KINASE 1A; EPIDERMAL GROWTH FACTOR RECEPTOR; HARMINE; INDOLE DERIVATIVE; INTERLEUKIN 6; INTERLEUKIN 8; LAMELLARIN; LEUCETTAMINE B; LEUCETTINE L41; MESSENGER RNA; MESSENGER RNA PRECURSOR; NATURAL PRODUCT; NOTCH RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; DYRK KINASE; PROTEIN SERINE THREONINE KINASE; PYRIDAZINE DERIVATIVE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; BRAIN CANCER; BRAIN DEVELOPMENT; CELL CYCLE; CELL DIFFERENTIATION; CHEMICAL STRUCTURE; DEGENERATIVE DISEASE; DOWN SYNDROME; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE SYSTEM; NEURAL STEM CELL; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; RNA SPLICING; SIGNAL TRANSDUCTION; ALTERNATIVE RNA SPLICING; ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; GENE DOSAGE; GENETICS; METABOLISM; NEOPLASMS; NEURODEGENERATIVE DISEASES;

ALTERNATIVE SPLICING; ALZHEIMER DISEASE; APOPTOSIS; BENZOTHIAZOLES; CELL CYCLE; CELL DIFFERENTIATION; DOWN SYNDROME; ENZYME ACTIVATION; GENE DOSAGE; HARMINE; HUMANS; INDOLES; NEOPLASMS; NEURODEGENERATIVE DISEASES; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; PYRIDAZINES; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 84930087450     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2015.03.004     Document Type: Review

References (102)

1. S. Abekhoukh, C. Planque, C. Ripoll, P. Urbaniak, J.-L. Paul, and J.-M. Delabar Dyrk1A, a serine/threonine kinase, is involved in ERK and Akt activation in the brain of hyperhomocysteinemic mice Mol Neurobiol 47 2013 105 116
2. T. Adayev, M.-C. Chen-Hwang, N. Murakami, E. Lee, D.C. Bolton, and Y.-W. Hwang Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro Biochemistry 46 2007 7614 7624
3. R. Albores, E.J. Neafsey, G. Drucker, J.Z. Fields, and M.A. Collins Mitochondrial respiratory inhibition by N-methylated beta-carboline derivatives structurally resembling N-methyl-4-phenylpyridine Proc Natl Acad Sci U S A 87 1990 9368 9372
4. L.A. Allan, and P.R. Clarke Phosphorylation of caspase-9 by CDK1/Cyclin B1 protects mitotic cells against poptosis Mol Cell 26 2007 301 310
5. L.A. Allan, N. Morrice, S. Brady, G. Magee, S. Pathak, and P.R. Clarke Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK Nat Cell Biol 5 2003 647 654
6. M. Alvarez, X. Altafaj, S. Aranda, and S. de la Luna DYRK1A Autophosphorylation on serine residue 520 modulates its kinase activity via 14-3-3 binding Mol Biol Cell 18 2007 1167 1178
7. K. Anderson, Y. Chen, Z. Chen, R. Dominique, K. Glenn, and Y. He Pyrido[2,3-d]pyrimidines: Discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors Bioorg Med Chem Lett 23 2013 6610 6615
8. J.R. Arron, M.M. Winslow, A. Polleri, C.-P. Chang, H. Wu, and X. Gao NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21 Nature 441 2006 595 600
9. K.-H. Baek, A. Zaslavsky, R.C. Lynch, C. Britt, Y. Okada, and R.J. Siarey Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1 Nature 459 2009 1126 1130
10. J. Bain, H. McLauchlan, M. Elliott, and P. Cohen The specificities of protein kinase inhibitors: an update Biochem J 371 2003 199 204
11. J. Bain, L. Plater, M. Elliott, N. Shpiro, C.J. Hastie, and H. McLauchlan The selectivity of protein kinase inhibitors: a further update Biochem J 408 2007 297 315
12. W. Becker, U. Soppa, and F. Tejedor DYRK1A: A POtential drug target for multiple Down syndrome neuropathologies CNS Neurol Disord Drug Targets 13 2014 26 33
13. S. Boichuk, J.A. Parry, K.R. Makielski, L. Litovchick, J.L. Baron, and J.P. Zewe The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis Cancer Res 73 2013 5120 5129
14. A. Bruel, R. Bénéteau, M. Chabanne, O. Lozach, R. Le Guevel, and M. Ravache Synthesis of new pyridazino[4,5-b]indol-4-ones and pyridazin-3(2H)-one analogs as DYRK1A inhibitors Bioorg Med Chem Lett 24 2014 5037 5040
15. H.-S. Chang, C.-H. Lin, C.-H. Yang, M.-S. Yen, C.-R. Lai, and Y.-R. Chen Increased expression of Dyrk1a in HPV16 immortalized keratinocytes enable evasion of apoptosis Int J Cancer 120 2007 2377 2385
16. J.-Y. Chen, J.-R. Lin, T. Feng-Chiao, and T. Meyer Dosage of Dyrk1A shifts cells within a p21-cyclin D1 signalling map to control the decision to enter the cell cycle Mol Cell 52 2013 87 100
17. J. Chen, and W.A. Weiss Alternative splicing in cancer: implications for biology and therapy Oncogene 34 2015 1 14
18. A. Contestabile, T. Fila, C. Ceccarelli, P. Bonasoni, L. Bonapace, and D. Santini Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with down syndrome and in Ts65Dn mice Hippocampus 17 2007 665 678
19. T.C. Coombs, C. Tanega, M. Shen, J.L. Wang, D.S. Auld, and S.W. Gerritz Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: Development of chemical probe ML315 Bioorg Med Chem Lett 23 2013 3654 3661
20. P.E. Czabotar, G. Lessene, A. Strasser, and J.M. Adams Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy Nat Rev Mol Cell Biol 15 2014 49 63
21. K. de Graaf, H. Czajkowska, S. Rottmann, L. Packman, R. Lilischkis, and B. Luscher The protein kinase DYRK1A phosphorylates the splicing factor SF3b1/SAP155 at Thr434, a novel in vivo phosphorylation site BMC Biochem 7 2006 7
22. R. De la Torre, S. De Sola, M. Pons, A. Duchon, M.M. de Lagran, and M. Farré Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans Mol Nutr Food Res 58 2014 278 288
23. M. Debdab, F.O. Carreaux, S. Renault, M. Soundararajan, O. Fedorov, and P. Filippakopoulos Leucettines, a class of potent inhibitors of cdc2-Like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: Modulation of alternative pre-RNA splicing J Med Chem 54 2011 4172 4186
24. J. Debray, S. Bonte, O. Lozach, L. Meijer, and M. Demeunynck Catalyst-free synthesis of quinazolin-4-ones from (hetero)aryl-guanidines: application to the synthesis of pyrazolo[4,3-f]quinazolin-9-ones, a new family of DYRK1A inhibitors Mol Divers 16 2012 659 667
25. O. Dehbi, A. Tikad, S. Bourg, P. Bonnet, O. Lozach, and L. Meijer Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors Eur J Med Chem 80 2014 352 363
26. X. Deng, D.Z. Ewton, and E. Friedman Mirk/Dyrk1B maintains the viability of quiescent pancreatic cancer cells by reducing levels of reactive oxygen species Cancer Res 69 2009 3317 3324
27. M. Dierssen Down syndrome: the brain in trisomic mode Nat Rev Neurosci 13 2012 844 858
28. B. Drung, C. Scholz, V.A. Barbosa, A. Nazari, M.H. Sarragiotto, and B. Schmidt Computational & experimental evaluation of the structure/activity relationship of β-carbolines as DYRK1A inhibitors Bioorg Med Chem Lett 24 2014 4854 4860
29. D.Z. Ewton, J. Hu, M. Vilenchik, X. Deng, K.-C. Luk, and A. Polonskaia Inactivation of Mirk/Dyrk1b kinase targets quiescent pancreatic cancer cells Mol Cancer Ther 10 2011 2104 2114
30. J. Fernandez-Martinez, E.M. Vela, M. Tora-Ponsioen, O.H. Ocaña, M.A. Nieto, and J. Galceran Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A J Cell Sci 122 2009 1574 1583
31. I. Ferrer, T. Gomez-Isla, B. Puig, M. Freixes, E. Ribe, and E. Dalfo Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies Curr Alzheimer Res 2 2005 3 18
32. S.R. Ferron, N. Pozo, A. Laguna, S. Aranda, E. Porlan, and M. Moreno Regulated segregation of kinase Dyrk1A during asymmetric neural stem cell division is critical for EGFR-mediated biased signaling Cell Stem Cell 7 2010 367 379
33. J.Z. Fields, R. Albores, E.J. Neafsey, and M.A. Collins Similar inhibition of mitochondrial respiration by 1-methyl-4-phenyl-pyridinium (MPP+) and by a unique N-methylated beta-carboline analogue, 2,9-dimethyl-norharman (2,9Me2NH)a Ann N Y Acad Sci 648 1992 272 274
34. A. Foucourt, D. Hédou, C. Dubouilh-Benard, L. Désiré, A.-S. Casagrande, and B. Leblond Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part I Molecules 19 2014 15546 15571
35. A. Foucourt, D. Hédou, C. Dubouilh-Benard, A. Girard, T. Taverne, and A.-S. Casagrande Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A Inhibitors, Part II Molecules 19 2014 15411 15439
36. D. Frost, B. Meechoovet, T. Wang, S. Gately, M. Giorgetti, and I. Shcherbakova β-Carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites PLoS One 6 2011 e19264
37. F. Giraud, G. Alves, E. Debiton, L. Nauton, V. Théry, and E. Durieu Synthesis, protein kinase inhibitory potencies, and in vitro antiproliferative activities of meridianin derivatives J Med Chem 54 2011 4474 4489
38. N. Göckler, G. Jofre, C. Papadopoulos, U. Soppa, F.J. Tejedor, and W. Becker Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation FEBS J 276 2009 6324 6337
39. S. Gourdain, J. Dairou, C. Denhez, L.C. Bui, F. Rodrigues-Lima, and N. Janel Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity J Med Chem 56 2013 9569 9585
40. P. Grabher, E. Durieu, E. Kouloura, M. Halabalaki, L.A. Skaltsounis, and L. Meijer Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts Planta Med 78 2012 951 956
41. X. Guo, J.G. Williams, T.T. Schug, and X. Li DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1 J Biol Chem 285 2010 13223 13232
42. Y. Gwack, S. Sharma, J. Nardone, B. Tanasa, A. Iuga, and S. Srikanth A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT Nature 441 2006 646 650
43. KIP1 expression and suppressing NOTCH signaling Development 138 2011 2543 2554
44. S. Himpel, W. Tegge, R. Frank, S. Leder, H.G. Joost, and W. Becker Specificity determinants of substrate recognition by the protein kinase DYRK1A J Biol Chem 275 2000 2431 2438
45. C. Holgren, U. Dougherty, F. Edwin, D. Cerasi, I. Taylor, and A. Fichera Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas Oncogene 29 2010 5241 5253
46. S.M. Jang, S. Azebi, G. Soubigou, and C. Muchardt DYRK1A phoshorylates histone H3 to differentially regulate the binding of HP1 isoforms and antagonize HP1-mediated transcriptional repression EMBO Rep 15 2014 686 694
47. R. Kageyama, T. Ohtsuka, H. Shimojo, and I. Imayoshi Dynamic regulation of Notch signaling in neural progenitor cells Curr Opin Cell Biol 21 2009 733 740
48. P.A. Kelly, and Z. Rahmani DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf and MEK1 Mol Biol Cell 16 2005 3562 3573
49. H. Kentrup, W. Becker, J. Heukelbach, A. Wilmes, A. Schürmann, and C. Huppertz Dyrk, a dual specificity protein kinase with unique structural features whose activity is dependent on tyrosine residues between subdomains VII and VIII J Biol Chem 271 1996 3488 3495
50. M.-Y. Kim, B.C. Jeong, J.H. Lee, H.J. Kee, H. Kook, and N.S. Kim A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells Proc Natl Acad Sci 103 2006 13074 13079
51. H.-S. Kim, M.J. Quon, and J.-A. Kim New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate Redox Biol 2 2014 187 195
52. H. Kim, S.O. Sablin, and R.R. Ramsay Inhibition of monoamine oxidase A by β-carboline derivatives Arch Biochem Biophys 337 1997 137 142
53. E.J. Kim, J.Y. Sung, H.J. Lee, H. Rhim, M. Hasegawa, and T. Iwatsubo Dyrk1A phosphorylates α-Synuclein and enhances intracellular inclusion formation J Biol Chem 281 2006 33250 33257
54. R. Kimura, K. Kamino, M. Yamamoto, A. Nuripa, T. Kida, and H. Kazui The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease Hum Mol Genet 16 2007 15 23
55. N. Kurabayashi, T. Hirota, M. Sakai, K. Sanada, and Y. Fukada DYRK1A and glycogen synthase kinase 3β, a dual-kinase mechanism directing proteasomal degradation of CRY2 for circadian timekeeping Mol Cell Biol 30 2010 1757 1768
56. Y. Lee, J. Ha, H.J. Kim, Y.-S. Kim, E.-J. Chang, and W.-J. Song Negative feedback inhibition of NFATc1 by DYRK1A regulates bone homeostasis J Biol Chem 284 2009 33343 33351
57. J.-M. Liao, X. Zhou, Y. Zhang, and H. Lu MiR-1246: A new link of the p53 family with cancer and Down syndrome Cell Cycle 11 2012 2624 2630
58. L. Litovchick, L.A. Florens, S.K. Swanson, M.P. Washburn, and J.A. DeCaprio DYRK1A protein kinase promotes quiescence and senescence through DREAM complex assembly Genes Dev 25 2011 801 813
59. F. Liu, Z. Liang, J. Wegiel, Y.-W. Hwang, K. Iqbal, and I. Grundke-Iqbal Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome FASEB J 22 2008 3224 3233
60. Q. Liu, N. Liu, S. Zang, H. Liu, P. Wang, and C. Ji Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc PLoS One 9 2014 e98853
61. Y. Loidreau, P. Marchand, C. Dubouilh-Benard, M.-R. Nourrisson, M. Duflos, and N. Loaëc Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases Eur J Med Chem 59 2013 283 295
62. B. Maenz, P. Hekerman, E.M. Vela, J. Galceran, and W. Becker Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1 BMC Mol Biol 9 2008 30
63. S. Malinge, M. Bliss-Moreau, G. Kirsammer, L. Diebold, T. Chlon, and S. Gurbuxani Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome J Clin Invest 122 2012 948 962
64. M. Mariano, C. Schmitt, P. Miralinaghi, M. Catto, R.W. Hartmann, and A. Carotti First selective dual inhibitors of tau phosphorylation and beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's isease ACS Chem Neurosci 5 2014 1198 1202
65. S. Masoumi-Moghaddam, A. Amini, and D. Morris The developing story of Sprouty and cancer Cancer Metastasis Rev 33 2014 695 720
66. M. Moore, Q. Wang, C. Kennedy, and P. Silver An alternative splicing network links cell cycle control to apoptosis Cell 142 2010 625 636
67. L. Munoz, R. Selig, Y. Yeung, C. Peifer, and S.A. Laufer Fluorescence polarisation binding assay to develop inhibitors of inactive p38a mitogen-activated protein kinase Anal Biochem 401 2010 125 133
68. C. Neagoie, E. Vedrenne, F. Buron, J.-Y. Mérour, S. Rosca, and S. Bourg Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: A novel DYRK1A inhibitor class Eur J Med Chem 49 2012 379 396
69. L. Nguyen, A. Besson, J.I.-T. Heng, C. Schuurmans, L. Teboul, and C. Parras p27kip1 independently promotes neuronal differentiation and migration in the cerebral cortex Genes Dev 20 2006 1511 1524
70. L. Nguyen, A. Besson, J.M. Roberts, and F. Guillemot Coupling cell cycle exit, neuronal differentiation and migration in cortical neurogenesis Cell Cycle 5 2006 2314 2318
71. Y. Ogawa, Y. Nonaka, T. Goto, E. Ohnishi, T. Hiramatsu, and I. Kii Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A Nat Commun 1 2010 86
72. M. Okui, T. Ide, K. Morita, E. Funakoshi, F. Ito, and K. Ogita High-level expression of the Mnb/Dyrk1A gene in brain and heart during rat early development Genomics 62 1999 165 171
73. J. Park, Y. Oh, L. Yoo, M.-S. Jung, W.-J. Song, and S.-H. Lee Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells J Biol Chem 285 2010 31895 31906
74. J. Park, W.H. Song, and K. Chung Function and regulation of DYRK1A: Towards understanding Down syndrome Cell Mol Life Sci 66 2009 3235 3240
75. J. Park, E.J. Yang, J.H. Yoon, and K.C. Chung Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome Mol Cell Neurosci 36 2007 270 279
76. N. Pozo, C. Zahonero, P. Fernández, J.M. Liñares, A. Ayuso, and M. Hagiwara Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth J Clin Invest 123 2013 2475 2487
77. W. Qian, N. Jin, J. Shi, X. Yin, X. Jin, and S. Wang Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) enhances tau expression J Alzheimers Dis 37 2013 529 538
78. W. Qian, H. Liang, J. Shi, N. Jin, I. Grundke-Iqbal, and K. Iqbal Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A Nucleic Acids Res 39 2011 6161 6171
79. J. Reniers, S. Robert, R. Frederick, B. Masereel, S. Vincent, and J. Wouters Synthesis and evaluation of β-carboline derivatives as potential monoamine oxidase inhibitors Bioorg Med Chem 19 2011 134 144
80. A.S. Rosenthal, C. Tanega, M. Shen, B.T. Mott, J.M. Bougie, and D.-T. Nguyen Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk) Bioorg Med Chem Lett 21 2011 3152 3158
81. S.-R. Ryoo, H.K. Jeong, C. Radnaabazar, J.-J. Yoo, H.-J. Cho, and H.-W. Lee DYRK1A-mediated hyperphosphorylation of tau: A functional link between Down syndrome and Alzheimer's disease J Biol Chem 282 2007 34850 34857
82. S. Sadasivam, and J.A. DeCaprio The DREAM complex: master coordinator of cell cycle-dependent gene expression Nat Rev Cancer 13 2013 585 595
83. C. Schmitt, D. Kail, M. Mariano, M. Empting, N. Weber, and T. Paul Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk/Clk inhibitors PLoS One 9 2014 e87851
84. C. Schmitt, P. Miralinaghi, M. Mariano, R.W. Hartmann, and M. Engel Hydroxybenzothiophene ketones are efficient pre-mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1/4 ACS Med Chem Lett 5 2014 963 967
85. A. Seifert, L.A. Allan, and P.R. Clarke DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine FEBS J 275 2008 6268 6280
86. A. Seifert, and P.R. Clarke p38α- and DYRK1A-dependent phosphorylation of caspase-9 at an inhibitory site in response to hyperosmotic stress Cell Signal 21 2009 1626 1633
87. J. Shi, T. Zhang, C. Zhou, M.O. Chohan, X. Gu, and J. Wegiel Increased dosage of Dyrk1A alters alternative splicing factor (ASF)-regulated alternative splicing of tau in Down syndrome J Biol Chem 283 2008 28660 28669
88. B. Smith, F. Medda, V. Gokhale, T. Dunckley, and C. Hulme Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: A new avenue for a disease modifying treatment of Alzheimer's? ACS Chem Neurosci 3 2012 857 872
89. M. Soundararajan, A.K. Roos, P. Savitsky, P. Filippakopoulos, A.N. Ketenbach, and J.V. Olsen Structures of Down syndrome kinases, DYRKs, reveal mechanism of kinase activation and substarte recognition Structure 21 2013 986 996
90. T. Tahtouh, J.M. Elkins, P. Filippakopoulos, M. Soundararajan, G. Burgy, and E. Durieu Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B J Med Chem 55 2012 9312 9330
91. Y. Takayama, P. May, R.G.W. Anderson, and J. Herz Low density lipoprotein receptor-related protein 1 (LRP1) controls endocytosis and c-CBL-mediated ubiquitination of the platelet-derived growth factor receptor β (PDGFRβ) J Biol Chem 280 2005 18504 18510
92. N. Tebbutt, M.W. Pedersen, and T.G. Johns Targeting the ERBB family in cancer: couples therapy Nat Rev Cancer 13 2013 663 673
93. F.J. Tejedor, and B. Hämmerle MNB/DYRK1A as a multiple regulator of neuronal development FEBS J 278 2011 223 235
94. F. Tejedor, X.R. Zhu, E. Kaltenbach, A. Ackermann, A. Baumann, and I. Canal Minibrain: A new protein kinase family involved in postembryonic neurogenesis in Drosophila Neuron 14 1995 287 301
95. M. Varjosalo, S. Keskitalo, A. Van Drogen, H. Nurkkala, A. Vichalkovski, and R. Aebersold The protein interaction landscape of the human CMGC kinase group Cell Rep 3 2013 1306 1320
96. J. Wegiel, C.-X. Gong, and Y.-W. Hwang The role of DYRK1A in neurodegenerative diseases FEBS J 278 2011 236 245
97. Y. Woods, P. Cohen, W. Becker, R. Jakes, M. Goedert, and X. Wang The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Be at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase Biochem J 355 2001 609 615
98. O. Yabut, J. Domogauer, and G. D'Arcangelo Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells J Neurosci 30 2010 4004 4014
99. Q. Yang, S.A. Rasmussen, and J.M. Friedman Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study Lancet 359 2002 1019 1025
100. Y.T. Yeung, K.L. McDonald, T. Grewal, and L. Munoz Interleukins in glioblastoma pathophysiology: implications for therapy Br J Pharmacol 168 2013 591 606
101. X. Yin, N. Jin, J. Gu, J. Shi, J. Zhou, and C.-X. Gong Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted tau exon 10 inclusion J Biol Chem 287 2012 30497 30506
102. J. Zhang, and J.L. Manley Misregulation of pre-mRNA alternative splicing in cancer Cancer Discov 3 2013 1228 1237